Objectives: With rapidly increasing numbers of publications, assessments of study quality, reporting quality, and classification of studies according to their level of evidence or developmental stage have become key issues in weighing the relevance of new information reported. Diagnostic marker studies are often criticized for yielding highly discrepant and even controversial results. Much of this discrepancy has been attributed to differences in study quality. So far, numerous tools for measuring study quality have been developed, but few of them have been used for systematic reviews and metaanalysis. This is due to the fact that most tools are complicated and time consuming, suffer from poor reproducibility, and do not permit quantitative scoring.
Introduction
With rapidly increasing numbers of publications, assessments of study quality, reporting quality, and classification of studies according to their level of evidence or developmental stage have become key issues in weighing the relevance of new information reported. Diagnostic marker studies are often criticized for yielding highly discrepant and even controversial results [1, 2] . Thus, for an article on diagnostic accuracy of a molecular bladder cancer marker it is often nearly impossible to judge the methodological rigor of that study and to conclude whether the published results can be translated to clinical practice.
The International Bladder Cancer Network (IBCN) has adopted this problem for the area of diagnostic and prognostic biomarker research, focusing on studies related to bladder cancer. Recently, the Phases Reporting and Assessment Optimization (PHARAO) project has been proposed for developing a classification system to describe the developmental status of a given marker in analogy to the commonly accepted phases of clinical trials (phases I -IV) [3, 4] . In addition, the IBCN has initiated an analysis of published tools that are used to asses study quality and reporting quality of biomarker studies, exploiting the resources of the IBCN.
Although the use of such tools for the assessment of diagnostic marker trials is recommended, these have generally not been implemented by users, e.g. readers or reviewers. Some of them have been used in systematic reviews and metaanalyses or in education research [5] ; however, in many tools sufficient external validation remains pending. One important reason for underutilization of these tools in the urology community is that urology training programs in general do not incorporate education on trial design, management, and analysis for their residents; further difficulties of these instruments reside in thir deficiency to define what may be considered sufficient or adequate quality. This is in part due to the great variability in study settings and designs posing great challenges to a given tool with regard to its general applicability. As a consequence, application of most of the tools becomes rather complicated, further preventing their general use. These issues have fueled the development of numerous new instruments without finding a solution of existing problems.
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In this context, it is the purpose of this review to introduce, classify, and analyze relevant available assessment tools designed to evaluate studies on the diagnostic accuracy of bladder cancer molecular markers. By this initiative, the use of assessment tools should be supported and, eventually, their practicability and applicability should be improved.
Current tools
A systematic review of medical data bases by Dreier et al [6] identified 17 tools designed to assess studies investigating the diagnostic accuracy of molecular markers. Only the instruments generated after 2000 and those more frequently cited in the literature were considered for this review. For this review, the tools were divided into four categories, based upon their objective:
• Study Quality:
(e.g. Newcastle-Ottawa scale [7] , QUADAS [8] 
Study quality

Newcastle-Ottawa quality assessment Scale (NOS):
The NOS was designed to evaluate the quality of non-randomized studies, discriminating between case control trials and cohort studies [7] . Both scales include three categories with a total of 8 items (Tab. 1). When analyzing case control trials, NOS addresses three areas including selection, comparability, and exposure, whereas in cohort studies it includes selection, comparability, and outcome.
This scale was originally developed for application in systematic reviews and metaanalyses. A study can be awarded a maximum of one star for each numbered item within the selection and exposure categories in case control studies, or the selection and outcome categories in cohort studies. A maximum of two stars can be given for comparability, in either type of study, resulting in a maximum of 9 points. No cut-off for good or poor quality is provided. The questions are clear and apparently easy to answer; however, the options provided are difficult to apply to some study concepts. Furthermore, the NOS has been criticized for having a high inter-rater variability [14] [15] [16] [17] .
The discrimination between case-control studies and cohort trials, as well as its easy applicability, are important factors that explain why the NOS has been frequently used in the past, mainly for systematic reviews and metaanalyses [18, 19] .
QUality Assessment of studies of Diagnostic Accuracy (QUADAS):
The QUADAS instrument is presumably the most widely accepted tool for quality assessment. It is considered a retrospective instrument for evaluation of the methodological rigor of a study investigating the diagnostic accuracy of a given test.
The QUADAS tool was developed through a Delphi procedure eventually reducing an initial list of 28 items down to 14 questions [8] . The items include patient spectrum, reference standard, disease progression bias, verification bias, review bias, clinical review bias, incorporation bias, test execution, study withdrawals, and indeterminate results (Tab. 2). The QUADAS tool is presented together with recommendations for scoring each of the items included. The QUADAS tool provides a matrix in which readers can examine the internal and external validity of a study.
The majority of items included in QUADAS relate to bias (items 3, 4, 5, 6, 7, 10, 11, 12 and 14); only two items relate to variability (items 1 and 2) while three relate to reporting (items 8, 9 and 13). The questions posed are focused and clear; their accompanying guidelines appear helpful. However, there is much room for subjective interpretation since several items may be answered differently by reviewers based upon their individual perception. Any item may be answered with either "yes", "no", or "unclear"; however, no advice is provided on scoring, cut-off and, as a result, on classifying a study as having good or poor quality.
The QUADAS tool has experienced fairly frequent use predominantly within systematic reviews and metaanalyses. For bladder cancer markers Xia et al. [20] reported its use in a metaanalysis on the accuracy of survivin in the diagnosis of bladder cancer.
Several reports have been published regarding the external validation of QUADAS [21, 22] . Oliveira et al. [21] applied the QUADAS score alone and in combination with the STARD tool to assess a malaria test in a semi-quantitative way. A combination of QUADAS criteria and STARD criteria was compared (see discussion of STARD below) with the QUADAS criteria alone. Articles fulfilling at least 50% of QUADAS criteria were considered as having regular to good quality without providing a definition for this allocation. Of the 13 articles retrieved, 12 fulfilled at least 50% of QUADAS criteria; only two fulfilled the combined STARD/QUADAS criteria. The authors concluded that the STARD/QUADAS combination might have the potential to provide greater rigor when evaluating the quality of studies, given that it incorporates relevant information not contemplated in the QUADAS criteria alone.
Hollingworth et al. [22] used data from a systematic review of magnetic resonance spectroscopy (MRS) in the characterization of suspected brain tumors to provide a preliminary evaluation of the inter-rater reliability of QUADAS. Nineteen publications were distributed randomly to primary and secondary reviewers for dual independent assessment. Most studies in this review were judged to have used an accurate reference standard. There was good correlation (rho = 0.78) between reviewers in assessment of the overall number of quality criteria met. However, mean agreement for individual QUADAS questions was only fair (kappa = 0.22) and ranged from no agreement (kappa < 0) to moderate agreement (kappa = 0.58). These findings suggest that different reviewers will reach different conclusions when using QUADAS. These findings are similar to those observed by Whiting et al. [23] ,
reporting an adequate inter-rater reliability for individual items in the QUADAS checklist (range 50-100%, median 90%).
Recently, the QUADAS2 tool has been presented [9] . It basically follows the original QUADAS tool; however, items were now reduced down to 11 questions in four new domains (patient selection, index test(s), reference standard, and flow and timing) (tab. 3). In contrast to the original scale, the QUADAS2 tool provides advice on the rating of study quality. To date, experience concerning the use of this instrument is limited [24, 25] and external validation is underway.
Quality of reporting
Although the general quality of the study and the reporting are difficult to separate from each other, the QUADAS tool has already been supplemented in 2003 by another tool, specifically addressing the issue of quality of reporting.
STAndards for the Reporting of Diagnostic accuracy studies (STARD)
The STARD tool was developed to improve the quality of reporting in diagnostic accuracy studies [e.g. 10, 11] . It comprises 25 items, mirroring the classical sections of a manuscript including title, keywords, abstract (1 item), introduction (1 item), methods (11 items), results (11 items), and discussion (1 item). The reader may rate each item as either "present" or "absent" (Tab. 4).
Smidt and coworkers reported on external validation by applying the STARD tool to 32 diagnostic accuracy studies published in medical journals with an impact factor of at least 4 in 2000 [26] . All manuscripts were independently reviewed by two experts at the beginning of the study and again almost two years later.
The overall inter-assessment agreement for all items of the STARD statement was 85% (Cohen's kappa 0.70) varying from 63% to 100% for individual items. The interassessment reliability of the STARD checklist was satisfactory (ICC = 0.79 [95% CI:
0.62 to 0.89]). The authors concluded that although the overall reproducibility of the quality of reporting using the STARD statement was good, substantial differences were found for specific items. These disagreements were not likely caused by differences in the interpretation by the reviewers but rather by difficulties in assessing the reporting of these items due to lack of clarity within the articles.
In summary, despite some deficiencies concerning reproducibility, the STARD tool is a validated tool for the assessment of reporting quality. However, several issues have emerged with this tool. The underlying questions are not always easy to apply to a given manuscript. Further, no recommendations for scoring are provided that may allow classifying a manuscript as having sufficiently good reporting or not.
Study phases
The definition of study phases addresses the need to identify the current status of 
Phase II: Evaluation Studies for Clinical Utility
This phase involves optimization of the assay technique (e.g. standardization, automatization) and/or interpretation of the assay results. The ultimate goal of this phase is to develop hypotheses and to define standards that can be used to perform Phase III studies.
Phase II trials are mostly single-institutional studies. However, adequately sized and representative samples of patients may be easier to achieve in a large collaborative network with sufficient numbers of specimens to define and select the most appropriate set of samples. In addition, identifying the sources of variability during this phase of biomarker development is required for designing a Phase III study.
Based upon the results in such studies, adequate cut-off values will be defined for quantitative assays. It is essential that the outcome from Phase II studies is translated into hypotheses that form the basis for Phase III analyses.
Phase III: Confirmation Studies
In Phase III, hypotheses emerging from previous phase II studies are tested with sufficient power in a defined clinical setting using an independent, prospective and controlled cohort of patients. The clinical utility of a given marker assay, its performance, and interpretation are established in this phase, the aim of which is the generation of (evidence-based) information that may eventually be included into clinical guidelines.
Phase IV: Validation and Technology Transfer as Application Studies
The aims of Phase IV studies are (a) to transfer the techniques and established methods of the assays and other aspects of the technology into clinical practice; and (b) to evaluate the ability of investigators and clinicians at other institutions to apply these methods and interpret the results in a similar and comparable way.
The IBCN classification is easy to use; nevertheless, it has only been rarely applied in the past in systematic reviews [1] . 
Levels of evidence
Discussion
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The problem of defining the quality of a given study is as old as scientific
communication. An extensive literature search recently performed by Dreier et al. [6] yielded a total of 147 different tools developed to assess study quality. While there has been a focus on therapeutic trials in the past, more recently instruments for assessment of diagnostic studies have also been developed. The large number of different assessment tools suggests that none of them is accepted as a "perfect"
solution for the problem.
Doubtless, the challenge to develop a single tool which can be applied to all diagnostic studies is considerable. In contrast to clinical trials with similar designs comparing standard care vs. a new strategy using criteria defined by good clinical practice (GCP) guidelines, diagnostic trials may differ with regard to a variety of parameters. Furthermore, the quality of studies is heterogeneous and numerous methodological shortcomings are apparent in the design of diagnostic accuracy studies (Tab. 7). Finally, definition of study quality is difficult since expectations are different and viewpoints may vary.
One of the most widely used tools to asses study quality is the QUADAS instrument.
However, it has been designed -and thus far is exclusively used -for systematic reviews or metaanalyses [8] . One problem in using the QUADAS tool lies in the distinction between general study quality and reporting quality. Inevitably, the assessment of quality relates strongly to the reporting of results; a well-conducted study will score poorly in a quality assessment tool if the methods and results are not reported in sufficient detail. The intention of the STARD document was to complement quality assessment of diagnostic accuracy studies by providing a tool focusing on quality of reporting [10, 11] . However, this requires the use of a second instrument and, in consequence, additional time.
Studies failing to report on aspects of quality may be considered as having inferior quality since faulty reporting generally reflects faulty methods. When using QUADAS, another important factor to consider is the difference between bias and variability.
Study bias will limit the validity of the study results whereas variability may complicate the translation of study results into clinical practice.
It may be questioned whether a separate tool for assessment of reporting quality like STARD is necessary and reasonable, or if the study and the reporting quality are so closely linked that analysis along the STARD criteria is not likely to generate an added value with regard to study assessment [16] . In general, it would be considered preferable to assess overall quality using just a single tool.
A classification of the development phases concerning the status of a new test may well be necessary. The IBCN classification using a four phase scale (in analogy to the four phases of clinical trials) may constitute a first step in this direction [12] . Thus far, this classification is not generally accepted, despite its simplicity and similarity to clinical study phases. This may be partly due to a lack of precision in some of the definitions; however, the instrument is currently under review for further improvement.
The Oxford level of evidence (LoE) 2001/2009 scale has been widely accepted for
classifying the scientific impact of a new study [13] . This may be attributed to the facts that (1) it can be more or less universally applied to different study designs, (2) it is clearly structured and (3) it can be easily used. Furthermore, the LoE classification is a rapid procedure and feasible even for inexperienced scientists.
While the revised 2011 version provides more flexibility this feature makes the classification much more demanding since former LoE 1b studies may be downgraded to level 2, while convincing former level 3 studies might even be considered level 1 in the current system. However, this gain in flexibility may be traded in for a loss in reproducibility and discriminative power.
Neither QUADAS nor STARD can be used to provide a reproducible quantitative value or score for study or reporting quality. At best, the QUADAS instrument provides a qualitative assessment of study design, permitting the conclusion that weaknesses in certain parameters may alter some test findings more than others.
However, there are several reasons for not incorporating a quality score into QUADAS. Scores are necessary if the investigator intends to use a quantitative indicator of quality to provide weight in a meta-analysis, or if a continuous variable in a meta-regression is required. Since quality scores are very rarely used in these 13 ways, the authors of QUADAS felt no need to introduce such a score. They stated that definitions on how to weigh and calculate quality scores might be in fact arbitrary, thus preventing development of an objective quality score [8, 23] . In consequence, the application of scores without consideration of the individual items may dilute or entirely miss potential associations.
The authors of this review would challenge this line of reasoning, believing instead that it is necessary to add a semi-quantitative estimation of the quality of a given study. In particular, we believe that journal editors and reviewers should be highly interested in tools permitting quantifying quality in a score, thereby permitting a more transparent review process. Furthermore, existing quality assessment tools still include arbitrary and debatable items notwithstanding the care invested in the development process. Finally, it should be the intention of an assessment tool to permit estimates of study quality or reporting whether or not formal scoring is included.
Similar to the QUADAS instrument, the NOS has been developed for quality assessment in reviews and metaanalyses [7, 27] . In contrast to QUADAS, it permits a semi-quantitative scoring although no cut-off for good/poor quality studies is provided. In a recent validation trial the inter-rater reliability of the NOS varied from substantial for the length of follow-up to poor for both the selection of a non-exposed cohort and the fact that the outcome was not present at study outset [15, 16] .
Investigators reported no association between individual NOS items or overall NOS score and effect on estimates. Variable agreement for the NOS and the lack of evidence showing that it is able to discriminate studies with biased results underscores the need for more detailed guidance to apply this tool in systematic reviews [15, 16] .
In general, it may be hypothesized that reliability and reproducibility are better achieved by simpler instruments. Final conclusions cannot be drawn since systematic validation of intra-and inter-rater reproducibility has rarely been reported for assessment tools in general. In particular, information concerning the use of the instruments by reviewers/investigators with limited experience is lacking.
14 Based upon this analysis the authors feel that most instruments available are too complicated and time consuming for an application beyond systematic reviews and metaanalysis (e.g. in peer review or identifying the relevance of a study after reading the manuscript). The reason underlying is the desire to generate comprehensive (ideal) assessment tools covering all possible aspects of quality/reporting quality. In order to improve the current situation we see a need for two measures: first of all a simple and robust assessment tool should be developed and validated. In a second step journal editors and publishers must be encouraged to request reviewing on the basis of such a tool. Acceptance by the reviewers can be obtained if the alternate review process will not require additional time.
As a starting point the IBCN is planning to support assessment of marker studies through investigation of existing tools for analysis of studies on diagnostic accuracy, delineating limitations, proposing modifications, or, if considered necessary, developing new tools targeting the needs of potential users. Embedded in the PHARAO initiative, the IBCN is preparing a validation trial for assessment tools focusing on studies on diagnostic accuracy. Instruments directed towards the assessment of study quality and reporting quality will be studied. In addition, further classification instruments for study phases and LoE will be included in this project.
Tables:
CASE CONTROL STUDIES COHORT STUDIES
A study can be awarded a maximum of one star for each numbered item within the Selection and Exposure categories. A maximum of two stars can be given for Comparability.
A study can be awarded a maximum of one star for each numbered item within the Selection and Outcome categories. A maximum of two stars can be given for Comparability 3) Adequacy of follow up of cohorts a) complete follow up -all subjects accounted for  b) subjects lost to follow up unlikely to introduce bias -small number lost -> ____ % (select an adequate %) follow up, or description provided of those lost)  c) follow up rate < ____% (select an adequate %) and no description of those lost d) no statement Table 1 : NOS items for assessment of study quality of diagnostic studies [5] .
19 Table 2 : QUADAS tool for assessment of study quality of diagnostic studies [6] . Table 3 : QUADAS-2 tool for assessment of study quality of diagnostic studies [9] . Case-series (and poor quality prognostic cohort studies)
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Case-control study, poor or non-independent reference standard 5
Expert opinion without explicit critical appraisal, or based on physiology, bench research or "first principles"
Expert opinion without explicit critical appraisal, or based on physiology, bench research or "first principles" " Clinical Decision Rule. (These are algorithms or scoring systems that lead to a prognostic estimation or a diagnostic category.) § § § Split-sample validation is achieved by collecting all the information in a single tranche, then artificially dividing this into "derivation" and "validation" samples.
" " An "Absolute SpPin" is a diagnostic finding whose Specificity is so high that a Positive result rules-in the diagnosis. An "Absolute SnNout" is a diagnostic finding whose Sensitivity is so high that a Negative result rules-out the diagnosis. 
